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During the past years the use of glycolipids as 
immunostimulating agents has become increasingly important.1,2 
When presented by the major histocompatibility complex (MHC) 
class I-like molecule CD1d, certain glycolipids are recognized by 
the semi-invariant T cell receptors (TCR) of natural killer T 
(NKT) cells.3 The prototypical antigen for NKT cells is-
galactosyl ceramide (-GalCer; 1).4 Upon recognition of the 
CD1d--GalCer bimolecular complex by their TCR, NKT cells 
are activated, resulting in the rapid release of T helper 1 (Th1) 
and T helper 2 (Th2) cytokines.5  
As both Th1 and Th2 cytokines influence the outcome of 
different immune responses, disruption of the carefully controlled 
Th1/Th2 balance can lead to disease induction and progression. 
While certain autoimmune diseases are characteristic of 
hyporesponsiveness to Th2 and overactivation of pathogenic Th1 
cells, the opposite is true for many types of cancer that have a 
predominant Th2 response. Hence, -GalCer analogues that 
induce a biased Th1/Th2 response are highly awaited.  
Attempts to selectively control the rapid secretion of cytokines 
by NKT cells have led to the development of several -GalCer 
analogs with interesting immunomodulatory properties (Chart 1). 
With the synthesis of OCH (2), a direct relationship has been 
shown between the shortening of lipid tail lengths and biasing of 
the cytokine release profile toward a Th2 response.6 Porcelli 
reported that substituting the N-acyl chain of -GalCer with 
shorter, unsaturated fatty acids modifies the outcome of V14i 
NKT cell activation.7 Analogues containing multiple cis-double 
bonds in the acyl chain (e.g., 5) potently induced a Th2-biased 
cytokine response. Conversely, Wong et al. have found that 
introduction of terminal aromatic groups into the fatty acyl tail (as 
in 6) biases the profile toward a Th1 response.8 
A proof-of-principle that -GalCer analogues capable of 
skewing the cytokine release profile may translate in an improved 
therapeutical outcome was established with -C-GalCer (3). 
Characterized by a marked Th1 response, this compound exhibits 
markedly improved activity against melanoma metastases and 
malaria compared with -GalCer.9 Bittman recently reported a 
truncated non-isosteric C-glycoside, termed -1C-GalCer (4), 
which produced less IFN- than -GalCer, but showed higher 
IFN-/IL-4 and IFN-/IL-13 ratios, typical for a Th1-immune 
response.10  
In 2005, the crystal structures of human11 and mouse12 CD1d 
complexed with -GalCer or a short-chain variant were 
elucidated, revealing that the galactose ring is well ordered and 
extends above the surface of a lipid-binding groove. Different 
intermolecular hydrogen bonds are assumed to anchor -GalCer 
in a proper orientation for recognition by the TCR of NKT cells. 
 Chart 1. Structures of selected -galactosyl ceramides 
 
Recently, Borg et al. reported the structure of a human NKT 
TCR in complex with CD1d bound to -GalCer.13 Consistent 
with the previously proposed structures,11,12 -GalCer protrudes 
minimally from the CD1d cleft with only the galactosyl head 
group exposed for recognition by the NKT TCR and interacting 
solely with its CDR1and CDR3loops. The galactose ring is 
sandwiched between Trp-153 of CD1d and the aliphatic moiety of 
Arg-95. The 2’-OH, 3’-OH and 4’-OH of the galactose ring 
form hydrogen bonds with amino acid residues of the invariant 
TCR -chain. This mode of binding is consistent with the 
specificity the NKT TCR exhibits for -GalCer versus closely 
related analogues modified at the sugar part.14 
Interestingly, the Gal 6’-OH is the only sugar alcohol not 
involved in H-bond formation, suggesting the possibility of 
introducing modifications at that position. In this respect, we were 
attracted to a report from Savage et al. who attached small 
fluorophores at that position, resulting in modified  -GalCers 
that retained the capacity to stimulate NKT cells.15 As it was 
envisioned that extra interactions might be established between 
CD1d and a 6’-OH modified -GalCer, it was decided to 
investigate such analogues.  
The synthetic strategy was similar to that used by Savage,15 
however, we chose to protect the secondary hydroxyl groups of 
the phytoceramide aglycon as benzyl ethers to facilitate the final 
deprotection (Scheme 1). Furthermore, to avoid solubility 
problems, the final debenzylation step was performed after 
modification of the 6’-amino group. The synthesis of 6’-azido-6’-
deoxygalactosylceramide 9 started from the D-ribo-
phytosphingosine building block 8.16 Mukaiyama glycosidation17 
involving 715 as the donor afforded the desired -glycoside 9 in 
46% yield. Reaction of the crude amine 10, obtained by 
Staudinger reduction of 9, with the appropriate acid and EDC as 
the coupling reagent, followed by hydrogenolysis of the benzyl 
groups, gave the desired amide analogues 11-14. Treatment of 10 
with the appropriate isocyanates afforded, after final deprotection, 
the 6’-ureido-6’-deoxygalactosylceramide analogues 15-19. 
Scheme 1. Synthesis of NKT cell agonists 11-19  
  
Scheme I. Reagents (yields in parentheses): a) SnCl2, AgClO4, THF, 4 
Ǻ MS, -10 °C to rt, 2h (46%); b) (i) PMe3, THF, rt, 4h; (ii) NaOH 1M, rt, 
2h (quant.); c) R-COOH, EDC, DMF, 4h, rt; d) R-NCO, DMF, 0 °C to rt, 
2h; d) H2, Pd black, CHCl3/EtOH: 1/3, 5h (33-65% over 2 steps).  
All analogues were tested by measuring the serum cytokine 
levels after injection into C57Bl/6 mice. Based on their ability to 
induce significantly reduced IL-4 production and comparable 
levels of IFN- compared to -GalCer (Figure 1), 12-19 were 
identified as Th1-skewing compounds.  
Figure 1. INF- and IL-4 secretion after intraperitoneal injection of -
GalCer and 11-19 in mice (** P < 0.05 and * P < 0.01 vs -GalCer). 
Considerably reduced IL-4 production was especially observed 
for the amides 12-14, which still induced reasonable levels of 
IFN-. Remarkably, the unsubstituted benzamide 11 failed to 
induce a strong Th1 response, which could be restored by the 
introduction of electron-witdrawing substituents on the aromate. 
In general, levels of both cytokines were higher for the urea 
derivates compared to the amide derivatives, although the latter 
showed a more pronounced Th-1 bias. Compound 14, featuring a 
3-CF3,4-Cl-benzamide substituent, emerged as the most 
promising Th1 polarizing agent, since it induced IFN- levels 
comparable to -GalCer, and only marginal levels of IL-4. No 
cytokine induction was observed when 11-19 were injected into 
J18-/- mice, indicating a TCR-dependent activation of NKT cells.  
Although numerous factors likely play a role in shifting the 
cytokine profile, stability of the CD1d/glycolipid complex is 
believed to be a contributing cause.18 Affirmatively, most of the 
known -GalCer analogues able to induce polarized cytokine 
responses are characterized by modifications of the 
phytosphingosine or fatty acyl chains, expected to alter the 
affinity for CD1d. For the first time a series of -GalCer 
analogues has been identified with an intact phytoceramide 
moiety, which are capable to skew the cytokine release profile to 
Th1 and possess a comparable ability to induce INF-secretion as 
-GalCer. In contrast to modifications of other Gal OH-
groups,14a-c these analogues clearly retain antigenic activity. 
Possibly the 6'-derivatives enjoy additional hydrophobic 
interactions, that increase binding with CD1d, resulting in the 
cytokine polarization. It is interesting to observe that at least in 
the amide series, electron withdrawing substituents on the aryl 
ring tend to induce the most promising Th1 cytokine profile. 
Interestingly, in the proximity of the 6’-position hCD1d 
structurally differs from mCD1d in that it contains a Trp-153 
instead of Gly-155.19 Hence, interaction with the electron 
rich indole ring could lead to additional effect on the cytokine 
polarisation.20 In vitro assays to investigate the effect of our 
analogues using human antigen presenting cells are in progress.   
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 -Galactosyl ceramide (-GalCer, also known as KRN 7000) is known as the prototypical antigen for invariant natural killer T 
(NKT) cells. Stimulation of NKT cells by CD1d-mediated -GalCer presentation leads to rapid release of Th1 and Th2 
cytokines. Since Th1 and Th2 cytokines antagonize each other’s effects, -GalCer analogues that induce a biased Th1/Th2 
response are highly awaited. With the exception of a C-glycoside (-C-GalCer), most of the known -GalCer analogues able 
to induce polarized cytokine responses are characterized by modifications of the phytosphingosine or fatty acyl chains, 
expected to alter the affinity for CD1d. 
Herein we describe the synthesis of 6’-modified -GalCer analogues with an intact phytoceramide moiety that are capable to 
skew the cytokine release profile to Th1, while maintaining strong antigenic activity. These analogues are characterized by the 
presence of an aromatic moiety that is connected via an amide or an urea linkage to C’-6 of the galactopyranose ring.  
